Tell me about diabetes
Reading File
Finding Sources
Searching PubMed
"diabetes mellitus"[MeSH Terms] AND "management"[MeSH Terms]
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile a thorough overview.
Diabetes Mellitus — A Comprehensive Overview
Definition
Diabetes mellitus (DM) is a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The resulting hyperglycemia, over time, damages blood vessels and nerves throughout the body.
Classification
The ADA recognizes four major clinical types:
| Type | Mechanism |
|---|---|
| Type 1 DM (T1DM) | Autoimmune destruction of pancreatic β-cells → absolute insulin deficiency |
| Type 2 DM (T2DM) | Progressive loss of β-cell insulin secretion on a background of insulin resistance |
| Gestational DM (GDM) | Diagnosed during pregnancy; was not clearly overt diabetes before gestation |
| Other specific types | Monogenic (MODY, neonatal DM), exocrine pancreatic disease (cystic fibrosis), drug/chemical-induced (glucocorticoids, HIV therapy, post-transplant) |
— Creasy & Resnik's Maternal-Fetal Medicine
Type 1 Diabetes Mellitus
T1DM is a chronic autoimmune disease in which immune-mediated destruction of β-cells in the islets of Langerhans leads to absolute insulin deficiency. It accounts for 5–10% of all diabetes cases but is proportionally more common in younger patients and those of reproductive age.
Pathogenesis:
- Islet cell autoantibodies, anti-insulin antibodies, anti-GAD65 antibodies, and anti-islet antigen 2 antibodies are markers of the destructive immune response
- Occurs in genetically susceptible individuals; >60 genetic loci have been implicated, many involving the immune system
- Environmental triggers (particularly enteroviruses) are under investigation
Key clinical feature: Prone to diabetic ketoacidosis (DKA). Without insulin, fat stores are mobilized and ketone bodies (acetoacetate, β-hydroxybutyrate) accumulate, causing life-threatening metabolic acidosis.
— Creasy & Resnik's Maternal-Fetal Medicine
Type 2 Diabetes Mellitus
T2DM is the most common form of diabetes. Hyperglycemia arises from two defects:
- Impaired insulin secretion — β-cells fail to respond normally to rising plasma glucose
- Insulin resistance — liver, muscle, and adipose tissue respond poorly to insulin action
Neither defect alone is sufficient; the diabetic state usually requires both. T2DM patients typically produce enough insulin to prevent DKA but not enough to maintain euglycemia.
Metabolic Syndrome: Insulin resistance frequently co-exists with hypertension, obesity, elevated triglycerides, and low HDL cholesterol — collectively termed metabolic syndrome — affecting >45 million Americans. Each component independently accelerates atherosclerosis.
β-cell pathology: β-cells are often hyperplastic early in the disease but progressively fail over time.
— Medical Physiology (Boron & Boulpaep)
Insulin's Normal Physiology
Understanding DM requires understanding insulin's actions:
- Liver: Promotes glycogen synthesis, glycolysis, and lipogenesis; inhibits gluconeogenesis and glucose-6-phosphatase
- Muscle: Recruits GLUT4 transporters to the membrane, enhancing glucose uptake; promotes glycogen synthesis and protein synthesis
- Adipose: Promotes glucose uptake via GLUT4; stimulates fat storage; inhibits lipolysis
- Overall effect: Burns carbohydrates preferentially, sparing protein and fat stores
Exercise and insulin have synergistic effects on GLUT4 recruitment in muscle — this is the physiological basis for exercise as a diabetes treatment.
— Medical Physiology
Diagnosis
Any one of the following criteria is sufficient (in non-pregnant adults):
| Criterion | Threshold |
|---|---|
| Fasting plasma glucose (FPG) | ≥ 126 mg/dL (7.0 mmol/L) |
| 2-hour OGTT glucose | ≥ 200 mg/dL (11.1 mmol/L) |
| HbA1c | ≥ 6.5% |
| Random glucose with classic symptoms | ≥ 200 mg/dL |
Pre-diabetes: FPG 100–125 mg/dL or HbA1c 5.7–6.4%
HbA1c reflects average blood glucose over the prior 2–3 months. Interpretation may be affected by age, race/ethnicity, pregnancy, hemoglobinopathies, and recent transfusions.
— Tintinalli's Emergency Medicine; Lippincott Illustrated Reviews: Pharmacology
Acute Complications
Diabetic Ketoacidosis (DKA)
- Caused by absolute or relative insulin deficiency plus excess counter-regulatory hormones (glucagon, catecholamines, cortisol, growth hormone)
- Diagnostic criteria: glucose >250 mg/dL, pH <7.3, bicarbonate <15–18 mEq/L, β-hydroxybutyrate >3 mmol/L
- Most common in type 1 DM but can occur in type 2, especially with SGLT2 inhibitors
- Precipitants: new diagnosis, infection, missed insulin
- Treatment: insulin, IV fluids (NaCl), potassium replacement; bicarbonate if pH <6.9
- Mortality now <1% with treatment (was nearly 100% before insulin discovery)
Hyperosmolar Hyperglycemic State (HHS)
- No significant ketoacidosis; glucose >600 mg/dL, osmolality >320 mOsm/L
- Most common in older patients with type 2 DM; ~60% precipitated by infection
- Treatment: IV fluids first, then insulin and potassium
- Mortality: 5–20% (much higher than DKA)
— Tietz Textbook of Laboratory Medicine
Chronic Complications
The landmark DCCT (type 1) and UKPDS (type 2) trials established a direct link between sustained hyperglycemia and long-term complications. These include:
| Category | Examples |
|---|---|
| Microvascular | Diabetic retinopathy, nephropathy (proteinuria → CKD), neuropathy |
| Macrovascular | Coronary artery disease, stroke, peripheral arterial disease |
| Other | Gastroparesis, erectile dysfunction, infections, poor wound healing |
Tight glycemic control, blood pressure management, and lipid control can retard progression of all these complications.
Treatment
Type 1 DM
- Insulin is mandatory (absolute insulin deficiency)
- Physiologic regimen: ~50% basal (long-acting, e.g., glargine) + ~50% prandial (rapid-acting, e.g., lispro)
- Total daily dose typically 0.4–1 unit/kg/day
- Prandial dosing: often 1 unit per 15 g carbohydrate ("carb counting")
- Delivery: subcutaneous injection (syringe or pen), or insulin pump (CSII)
- Adjuncts: pramlintide (amylin analogue), β-cell or pancreas transplantation in select cases
Type 2 DM
- Lifestyle modification (diet, exercise) is first-line
- Metformin is the preferred initial oral agent
- Additional classes: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, thiazolidinediones, sulfonylureas
- Insulin therapy may be added as β-cell function declines
- Exercise increases insulin sensitivity through synergistic GLUT4 recruitment
— Tintinalli's Emergency Medicine; Medical Physiology
Epidemiology
Diabetes is a global epidemic. The IDF projects hundreds of millions of adults affected worldwide, with the largest growth in Southeast Asia and the Western Pacific. Type 2 DM accounts for ~90–95% of all cases. Obesity and physical inactivity are the primary drivers of the T2DM epidemic.
Key takeaway: Diabetes is not a single disease but a spectrum of disorders united by hyperglycemia. Management targets not just glucose but the entire cardiometabolic risk profile — blood pressure, lipids, weight, and kidney function — to reduce the enormous burden of complications.
This is a shared conversation. Sign in to Orris to start your own chat.